- Home
- Publications
- Publication Search
- Publication Details
Title
SARS-CoV-2 Antiviral Therapy
Authors
Keywords
-
Journal
CLINICAL MICROBIOLOGY REVIEWS
Volume -, Issue -, Pages -
Publisher
American Society for Microbiology
Online
2021-07-28
DOI
10.1128/cmr.00109-21
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Making sense of contradictory evidence in Covid-19 trials
- (2021) Ryan C Maves CLINICAL INFECTIOUS DISEASES
- Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial
- (2021) Patricia R. M. Rocco et al. EUROPEAN RESPIRATORY JOURNAL
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis
- (2021) Bryan A. Johnson et al. NATURE
- A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent
- (2021) Tianshu Xiao et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
- (2021) Romina Libster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
- (2021) Michael J. Joyner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
- (2021) Paul-Albert Koenig et al. SCIENCE
- Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188
- (2021) Gordon J. Lockbaum et al. Viruses-Basel
- Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies
- (2021) Maxwell T. Finkelstein et al. Viruses-Basel
- A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
- (2021) Cheolmin Kim et al. Nature Communications
- Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
- (2021) Goran Kokic et al. Nature Communications
- Pan-coronavirus fusion inhibitors as the hope for today and tomorrow
- (2021) Xinling Wang et al. Protein & Cell
- α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action
- (2021) Chengliang Yang et al. Lancet Respiratory Medicine
- Major Update: Remdesivir for Adults With COVID-19
- (2021) Anjum S. Kaka et al. ANNALS OF INTERNAL MEDICINE
- Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2
- (2021) Wendy P. Painter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19
- (2021) Steven S. Good et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Differentially conserved amino acid positions may reflect differences in SARS-CoV-2 and SARS-CoV behaviour
- (2021) Denisa Bojkova et al. BIOINFORMATICS
- SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
- (2021) Xiaoying Shen et al. Cell Host & Microbe
- Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
- (2021) Allison J. Greaney et al. Cell Host & Microbe
- Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19
- (2021) Eduardo López-Medina et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus
- (2021) Sumathi Sivapalasingam et al. JOURNAL OF INFECTIOUS DISEASES
- Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models
- (2021) Yingjun Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in the requirements for receptor expression and proteolytic activation
- (2021) Bojan F. Hörnich et al. JOURNAL OF VIROLOGY
- A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19
- (2021) Maren de Vries et al. JOURNAL OF VIROLOGY
- SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
- (2021) Angela Wahl et al. NATURE
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae
- (2021) Ashlee D. Brunaugh et al. PLoS One
- Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP
- (2021) Katerina Naydenova et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
- (2021) Kris M. White et al. SCIENCE
- Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets
- (2021) Rory D. de Vries et al. SCIENCE
- SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model
- (2021) Jingxin Qiao et al. SCIENCE
- A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication
- (2021) Shin-ichiro Hattori et al. Nature Communications
- Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
- (2021) Jerzy Osipiuk et al. Nature Communications
- Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2
- (2021) Ewelina Weglarz-Tomczak et al. Scientific Reports
- Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
- (2021) Jordan J Feld et al. Lancet Respiratory Medicine
- Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19
- (2021) Kas Steuten et al. ACS Infectious Diseases
- An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants
- (2021) Kui K. Chan et al. Science Advances
- Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
- (2021) Markus Hoffmann et al. EBioMedicine
- The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19
- (2021) Daniele Focosi et al. Life-Basel
- ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model
- (2021) Koen Vandyck et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor
- (2021) Rita Humeniuk et al. CLINICAL PHARMACOKINETICS
- A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19
- (2021) Junsaku Kitagawa et al. CTS-Clinical and Translational Science
- In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19
- (2021) Carolina Q Sacramento et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
- (2021) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- β-D-N 4-hydroxycytidine (NHC) Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
- (2021) Shuntai Zhou et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
- (2021) Katherine R W Emary et al. LANCET
- Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication
- (2021) Jack P.K. Bravo et al. MOLECULAR CELL
- Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
- (2021) Shuofeng Yuan et al. NATURE
- Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia
- (2021) Luca Braga et al. NATURE
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Delayed production of neutralizing antibodies correlates with fatal COVID-19
- (2021) Carolina Lucas et al. NATURE MEDICINE
- Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
- (2021) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Vivek Shinde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
- (2021) Phillip Pymm et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
- (2021) Bryan E. Jones et al. Science Translational Medicine
- Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19
- (2021) Meehyun Ko et al. Viruses-Basel
- Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
- (2021) Prasanna Jagannathan et al. Nature Communications
- Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
- (2021) Sho Iketani et al. Nature Communications
- Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
- (2021) Kyle Rosenke et al. Nature Communications
- Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection
- (2021) Lukas Wettstein et al. Nature Communications
- Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
- (2021) Cathrine Axfors et al. Nature Communications
- Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
- (2021) Vikas P. Sukhatme et al. Frontiers in Pharmacology
- Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities
- (2021) Myron S. Cohen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- SARS-CoV-2 variants, spike mutations and immune escape
- (2021) William T. Harvey et al. NATURE REVIEWS MICROBIOLOGY
- The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer
- (2020) Sundy N.Y. Yang et al. ANTIVIRAL RESEARCH
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
- (2020) Calvin J Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
- (2020) Guangdi Li et al. NATURE REVIEWS DRUG DISCOVERY
- Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus
- (2020) Steven S. Good et al. PLoS One
- Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
- (2020) Emmie de Wit et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
- (2020) Timothy P. Sheahan et al. Nature Communications
- Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
- (2020) Jimin Xu et al. ACS Infectious Diseases
- Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency
- (2020) Carlos Chaccour et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
- (2020) Sangeun Jeon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
- (2020) Markus Hoffmann et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade
- (2020) B. Coutard et al. ANTIVIRAL RESEARCH
- Structural basis for RNA replication by the SARS-CoV-2 polymerase
- (2020) Quan Wang et al. CELL
- Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
- (2020) Qihui Wang et al. CELL
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
- (2020) Daniel Blanco-Melo et al. CELL
- SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues
- (2020) Carly G.K. Ziegler et al. CELL
- Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
- (2020) Daniel Wrapp et al. CELL
- Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
- (2020) Vanessa Monteil et al. CELL
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Identification of Human Single-Domain Antibodies against SARS-CoV-2
- (2020) Yanling Wu et al. Cell Host & Microbe
- Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients
- (2020) Zhuo Zhou et al. Cell Host & Microbe
- Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
- (2020) Annsea Park et al. Cell Host & Microbe
- Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
- (2020) Shuai Xia et al. CELL RESEARCH
- Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019
- (2020) Juanjuan Zhao et al. CLINICAL INFECTIOUS DISEASES
- The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19
- (2020) Virginia D. Schmith et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
- (2020) Yin‐Xiao Du et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Lack of Antiviral Activity of Darunavir against SARS-CoV-2
- (2020) Sandra De Meyer et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
- (2020) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity
- (2020) Yuanmei Zhu et al. JOURNAL OF VIROLOGY
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- (2020) Yeming Wang et al. LANCET
- A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
- (2020) Markus Hoffmann et al. MOLECULAR CELL
- A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
- (2020) Rui Shi et al. NATURE
- Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
- (2020) Denisa Bojkova et al. NATURE
- Structure of replicating SARS-CoV-2 polymerase
- (2020) Hauke S. Hillen et al. NATURE
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
- (2020) Dora Pinto et al. NATURE
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
- (2020) David E. Gordon et al. NATURE
- Structural basis of receptor recognition by SARS-CoV-2
- (2020) Jian Shang et al. NATURE
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
- (2020) Zhenming Jin et al. NATURE
- Antibody responses to SARS-CoV-2 in patients with COVID-19
- (2020) Quan-Xin Long et al. NATURE MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 infection protects against rechallenge in rhesus macaques
- (2020) Abishek Chandrashekar et al. SCIENCE
- Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
- (2020) Wenhao Dai et al. SCIENCE
- Structure of the RNA-dependent RNA polymerase from COVID-19 virus
- (2020) Yan Gao et al. SCIENCE
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
- (2020) Linlin Zhang et al. SCIENCE
- Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
- (2020) Wanchao Yin et al. SCIENCE
- A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
- (2020) Meng Yuan et al. SCIENCE
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
- (2020) Timothy P. Sheahan et al. Science Translational Medicine
- Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
- (2020) Su-Jin Park et al. mBio
- A human monoclonal antibody blocking SARS-CoV-2 infection
- (2020) Chunyan Wang et al. Nature Communications
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
- (2020) Xiuyuan Ou et al. Nature Communications
- Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
- (2020) Changhai Lei et al. Nature Communications
- Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
- (2020) Wei Tang et al. BMJ-British Medical Journal
- Correction to: Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit
- (2020) Duxin Sun AAPS Journal
- Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19
- (2020) Caleb P. Skipper et al. ANNALS OF INTERNAL MEDICINE
- Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial
- (2020) Effat Davoudi-Monfared et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production
- (2020) Natalia Fintelman-Rodrigues et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19
- (2020) Steffen Jockusch et al. ANTIVIRAL RESEARCH
- Antiviral activities of type I interferons to SARS-CoV-2 infection
- (2020) Emily Mantlo et al. ANTIVIRAL RESEARCH
- Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
- (2020) Ashleigh Shannon et al. ANTIVIRAL RESEARCH
- Coronavirus membrane fusion mechanism offers a potential target for antiviral development
- (2020) Tiffany Tang et al. ANTIVIRAL RESEARCH
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
- (2020) Leon Caly et al. ANTIVIRAL RESEARCH
- Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
- (2020) Ka-Tim Choy et al. ANTIVIRAL RESEARCH
- Type 1 interferons as a potential treatment against COVID-19
- (2020) Erwan Sallard et al. ANTIVIRAL RESEARCH
- Beyond Antibodies: The DARPin® Drug Platform
- (2020) Michael T. Stumpp et al. BIODRUGS
- The Global Phosphorylation Landscape of SARS-CoV-2 Infection
- (2020) Mehdi Bouhaddou et al. CELL
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
- (2020) Chunlong Ma et al. CELL RESEARCH
- AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
- (2020) Andrey A Ivashchenko et al. CLINICAL INFECTIOUS DISEASES
- Dihydroorotate Dehydrogenase Inhibitors in SARS‐CoV‐2 Infection
- (2020) Ana R. Coelho et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Distinct Early Serological Signatures Track with SARS-CoV-2 Survival
- (2020) Caroline Atyeo et al. IMMUNITY
- Lactoferrin as potential preventative and adjunct treatment for COVID-19
- (2020) Raymond Chang et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial
- (2020) Fang Zheng et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Inhibition of SARS-CoV-2 by type I and type III interferons
- (2020) Ulrike Felgenhauer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19
- (2020) Minchen Chien et al. JOURNAL OF PROTEOME RESEARCH
- Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures
- (2020) Abigail Vanderheiden et al. JOURNAL OF VIROLOGY
- Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
- (2020) Markus Hoffmann et al. NATURE
- Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
- (2020) Brandi N. Williamson et al. NATURE
- Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
- (2020) Laura Riva et al. NATURE
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
- (2020) Lihong Liu et al. NATURE
- Potently neutralizing and protective human antibodies against SARS-CoV-2
- (2020) Seth J. Zost et al. NATURE
- Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
- (2020) Daming Zhou et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
- (2020) Jiangdong Huo et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
- (2020) Alexandre B. Cavalcanti et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
- (2020) David R. Boulware et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2
- (2020) Yuan-Lin Kang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
- (2020) Xiangyang Chi et al. SCIENCE
- Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
- (2020) Alina Baum et al. SCIENCE
- Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
- (2020) Jérôme Hadjadj et al. SCIENCE
- Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
- (2020) Kui K. Chan et al. SCIENCE
- Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
- (2020) Johanna Hansen et al. SCIENCE
- Distinct conformational states of SARS-CoV-2 spike protein
- (2020) Yongfei Cai et al. SCIENCE
- Broad neutralization of SARS-related viruses by human monoclonal antibodies
- (2020) Anna Z. Wec et al. SCIENCE
- The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner
- (2020) Mizuki Yamamoto et al. Viruses-Basel
- Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
- (2020) Victoria C. Yan et al. ACS Medicinal Chemistry Letters
- Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing
- (2020) Sepideh Sadegh et al. Nature Communications
- Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
- (2020) Andrea J. Pruijssers et al. Cell Reports
- Interplay between SARS-CoV-2 and the type I interferon response
- (2020) Margarida Sa Ribero et al. PLoS Pathogens
- Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2
- (2020) Rui Xiong et al. Protein & Cell
- The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
- (2020) Lakshmanane Premkumar et al. Science Immunology
- TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells
- (2020) Dorothea Bestle et al. Life Science Alliance
- A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19
- (2020) Yohei Doi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions
- (2020) So Young Kim et al. ANTIVIRAL RESEARCH
- Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
- (2020) Meng Yuan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- CoV-AbDab: the Coronavirus Antibody Database
- (2020) Matthew I J Raybould et al. BIOINFORMATICS
- SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2
- (2020) Thomas Mandel Clausen et al. CELL
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
- (2020) Luca Piccoli et al. CELL
- High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models
- (2020) Wei Li et al. CELL
- Accelerated preclinical paths to support rapid development of COVID-19 therapeutics
- (2020) Jay A. Grobler et al. Cell Host & Microbe
- Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)
- (2020) Juliana Cepelowicz Rajter et al. CHEST
- Treatment of COVID-19 Patients with Prolonged Post-Symptomatic Viral Shedding with Leflunomide -- a Single-Center, Randomized, Controlled Clinical Trial
- (2020) Mengmei Wang et al. CLINICAL INFECTIOUS DISEASES
- Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial
- (2020) Oriol Mitjà et al. CLINICAL INFECTIOUS DISEASES
- Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
- (2020) Theresa Klemm et al. EMBO JOURNAL
- Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
- (2020) Yan Lou et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
- (2020) Christoph D. Spinner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis
- (2020) Bryony Simmons et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action
- (2020) Egor P Tchesnokov et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
- (2020) Robert L. Hoffman et al. JOURNAL OF MEDICINAL CHEMISTRY
- The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells
- (2020) Shutoku Matsuyama et al. JOURNAL OF VIROLOGY
- Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.
- (2020) Kumari G. Lokugamage et al. JOURNAL OF VIROLOGY
- Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion
- (2020) Donald J. Benton et al. NATURE
- A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
- (2020) Kenneth H. Dinnon et al. NATURE
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
- (2020) Christopher O. Barnes et al. NATURE
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
- (2020) Ugur Sahin et al. NATURE
- Why big pharma has abandoned antibiotics
- (2020) Benjamin Plackett NATURE
- Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
- (2020) Colton J. Bracken et al. Nature Chemical Biology
- Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome
- (2020) Yaseen M. Arabi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
- (2020) Suzanne J. F. Kaptein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Engineered ACE2 receptor traps potently neutralize SARS-CoV-2
- (2020) Anum Glasgow et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms
- (2020) David E. Gordon et al. SCIENCE
- REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
- (2020) Alina Baum et al. SCIENCE
- De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
- (2020) Longxing Cao et al. SCIENCE
- Autoantibodies against type I IFNs in patients with life-threatening COVID-19
- (2020) Paul Bastard et al. SCIENCE
- Malleability of the SARS-CoV-2 3CL Mpro active site cavity facilitates binding of clinical antivirals
- (2020) Daniel W. Kneller et al. STRUCTURE
- GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection
- (2020) Shin-ichiro Hattori et al. mBio
- Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain
- (2020) Victor K. Outlaw et al. mBio
- Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2
- (2020) Idoia Busnadiego et al. mBio
- Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
- (2020) Mohammad M. Ghahremanpour et al. ACS Medicinal Chemistry Letters
- An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
- (2020) Leo Hanke et al. Nature Communications
- Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
- (2020) Lifeng Fu et al. Nature Communications
- A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
- (2020) Xuping Xie et al. Nature Communications
- Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis
- (2020) Ashleigh Shannon et al. Nature Communications
- Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
- (2020) Wayne Vuong et al. Nature Communications
- Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir
- (2020) Steffen Jockusch et al. Scientific Reports
- Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects
- (2020) Ya-Wen Cheng et al. Cell Reports
- Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease
- (2020) Cintia A. Menéndez et al. Science Advances
- Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial
- (2020) Khalil Ansarin et al. BioImpacts
- Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent
- (2020) Yili Xu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- COVID-19-neutralizing antibodies predict disease severity and survival
- (2020) Wilfredo F. Garcia-Beltran et al. CELL
- Potential SARS-CoV-2 main protease inhibitors
- (2020) Riddhidev Banerjee et al. DRUG DISCOVERY TODAY
- Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment
- (2020) Yan Wang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
- (2020) Eric J. Lenze et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19
- (2020) Oriol Mitjà et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
- (2020) Ventura A. Simonovich et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin
- (2020) Courtney J. Mycroft-West et al. THROMBOSIS AND HAEMOSTASIS
- Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time
- (2020) Timothy F. Czajka et al. TRENDS IN MICROBIOLOGY
- The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines
- (2020) Jeremy Luban et al. VIRUS RESEARCH
- IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro
- (2020) Friedrich Hahn et al. Viruses-Basel
- Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection In Vitro
- (2020) Francesca Curreli et al. mBio
- Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
- (2020) Xia Xiao et al. Frontiers in Immunology
- Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
- (2020) Robert M. Cox et al. Nature Microbiology
- Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM
- (2020) Cong Xu et al. Science Advances
- The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19
- (2020) Maksim V. Baranov et al. Cells
- Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
- (2020) Zarir F. Udwadia et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Phillip D Monk et al. Lancet Respiratory Medicine
- Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis
- (2019) Dorian A. Rosen et al. Science Translational Medicine
- Respiratory syncytial virus entry and how to block it
- (2019) Michael B. Battles et al. NATURE REVIEWS MICROBIOLOGY
- High-throughput Screening and Identification of Potent Broad-spectrum Inhibitors of Coronaviruses
- (2019) Liang Shen et al. JOURNAL OF VIROLOGY
- Shared and Distinct Functions of Type I and Type III Interferons
- (2019) Helen M. Lazear et al. IMMUNITY
- Nucleoside analogues for the treatment of coronavirus infections
- (2019) Andrea J Pruijssers et al. Current Opinion in Virology
- A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
- (2019) Shuai Xia et al. Science Advances
- IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes
- (2019) Rudragouda Channappanavar et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis
- (2019) Elina Berliba et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Comprehensive Superposition of Viral Polymerase Structures
- (2019) Olve Peersen Viruses-Basel
- New antibody-based prevention and treatment options for influenza
- (2019) Koen Sedeyn et al. ANTIVIRAL RESEARCH
- Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
- (2019) Maria L. Agostini et al. JOURNAL OF VIROLOGY
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
- (2019) Sabue Mulangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
- (2018) Leen Delang et al. ANTIVIRAL RESEARCH
- Niclosamide: Beyond an antihelminthic drug
- (2018) Wei Chen et al. CELLULAR SIGNALLING
- Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element
- (2018) Anushka C. Galasiti Kankanamalage et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study
- (2018) John H Beigel et al. LANCET INFECTIOUS DISEASES
- Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry
- (2018) Kazuya Shirato et al. VIROLOGY
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
- (2018) Maria L. Agostini et al. mBio
- De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery
- (2018) Chao Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Expert Consensus on Palivizumab use for Respiratory Syncytial Virus in Developed Countries
- (2018) Manuel Sánchez Luna et al. Paediatric Respiratory Reviews
- Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
- (2017) Dustin Siegel et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro , Ex Vivo , and In Vivo Antiviral Activity
- (2017) Huihui Chong et al. JOURNAL OF VIROLOGY
- Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA
- (2017) François Ferron et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
- (2017) Timothy P. Sheahan et al. Science Translational Medicine
- Single-Domain Antibodies As Therapeutics against Human Viral Diseases
- (2017) Yanling Wu et al. Frontiers in Immunology
- Human monoclonal antibodies as candidate therapeutics against emerging viruses
- (2017) Yujia Jin et al. Frontiers of Medicine
- Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice
- (2016) Rudragouda Channappanavar et al. Cell Host & Microbe
- Approved Antiviral Drugs over the Past 50 Years
- (2016) Erik De Clercq et al. CLINICAL MICROBIOLOGY REVIEWS
- Coronaviruses — drug discovery and therapeutic options
- (2016) Alimuddin Zumla et al. NATURE REVIEWS DRUG DISCOVERY
- SARS and MERS: recent insights into emerging coronaviruses
- (2016) Emmie de Wit et al. NATURE REVIEWS MICROBIOLOGY
- Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor
- (2016) Yunjeong Kim et al. PLoS Pathogens
- Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
- (2016) Jean-François Rossignol Journal of Infection and Public Health
- Protease inhibitors targeting coronavirus and filovirus entry
- (2015) Yanchen Zhou et al. ANTIVIRAL RESEARCH
- Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection
- (2015) Rudragouda Channappanavar et al. JOURNAL OF INFECTIOUS DISEASES
- Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis
- (2015) Jean Kaoru Millet et al. VIRUS RESEARCH
- Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
- (2014) Adriaan H. de Wilde et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
- (2014) Julie Dyall et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
- (2014) Lu Lu et al. Nature Communications
- The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis
- (2014) J. M. Lucas et al. Cancer Discovery
- Antiviral drugs specific for coronaviruses in preclinical development
- (2014) Adeyemi O Adedeji et al. Current Opinion in Virology
- Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner
- (2014) Christine Burkard et al. PLoS Pathogens
- Favipiravir (T-705), a novel viral RNA polymerase inhibitor
- (2013) Yousuke Furuta et al. ANTIVIRAL RESEARCH
- Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects
- (2013) Manuel Haschke et al. CLINICAL PHARMACOKINETICS
- Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
- (2013) Darryl Falzarano et al. Scientific Reports
- Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics
- (2013) Everett Clinton Smith et al. PLoS Pathogens
- Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry
- (2012) M. Kawase et al. JOURNAL OF VIROLOGY
- Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses
- (2012) Y. Kim et al. JOURNAL OF VIROLOGY
- SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon
- (2012) Allison L Totura et al. Current Opinion in Virology
- Timing of Oseltamivir Administration and Outcomes in Hospitalized Adults With Pandemic 2009 Influenza A(H1N1) Virus Infection
- (2011) Diego Viasus et al. CHEST
- Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans
- (2011) Jianshe Lang et al. PLoS One
- Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model
- (2010) Yohichi Kumaki et al. ANTIVIRAL RESEARCH
- Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates
- (2010) Saskia L. Smits et al. PLoS Pathogens
- A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo
- (2009) Craig W. Day et al. VIROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started